CANCER RESEARCH TRAINING AND EDUCATION COORDINATION (CRTEC) ? ABSTRACT Karmanos Cancer Institute (KCI) provides extensive cancer research training and educational programs that span all career stages. Dr. Michele Cote (PSDR), Associate Center Director for Education, leads KCI?s CRTEC efforts. In addition to identification, promotion, and support of University-sponsored training activities, Dr. Cote (PSDR) coordinates the cancer-specific programs at KCI. With the support of CRTEC Education Advisory Council members, each with expertise in a particular field or window of training, Dr. Cote (PSDR) serves as the main point of contact for trainees across the career trajectory. A key component of the CRTEC is to evaluate the effectiveness of the supported training activities, and identifying gaps and opportunities to enhance KCI training efforts across the spectrum. KCI?s education efforts span the education and training continuum including efforts focused on high school students, undergraduate students, graduate and medical students, post-doctoral trainees, residents and fellows, junior faculty, tenured faculty and community healthcare providers. CRTEC efforts are supported by ten active training projects totaling $895,210 direct costs. Several have grown out of a T32 led by Dr. Matherly (MT) (T32CA009531). This training program in the biology of cancer that has been continuously funded for over three decades. Since 2015, 24 students have been supported via the T32, five of whom were also awarded subsequent F30 or F31 support. Novel efforts at KCI include the launch of focuSStem in 2019, a program developed by a high school student, for high school students, with support from KCI leadership. In its inaugural year, five schools and 149 students have participated in the day-long program (37% African American, 30% non- Hispanic white, 27% Arab American, 4% Hispanic and 2% other races; over 50% females). A recent addition to our efforts in reaching high school students is the Discovery to Cure High School Internship Program (DTCHIP) (R25HD072591) led by Dr. Gil Mor (TBM) which will begin recruiting in the summer of 2020.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA022453-39
Application #
10088975
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1997-08-08
Project End
2025-11-30
Budget Start
2020-12-15
Budget End
2021-11-30
Support Year
39
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
McKnight, Brooke N; Viola-Villegas, Nerissa T (2018) Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging. Breast Cancer Res 20:130
McFall, Thomas; McKnight, Brooke; Rosati, Rayna et al. (2018) Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem 293:1163-1177
Dyson, Greg; Farran, Batoul; Bolton, Susan et al. (2018) The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. Am J Cancer Res 8:2088-2095
Greenwald, Mark K; Ruterbusch, Julie J; Beebe-Dimmer, Jennifer L et al. (2018) Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. Cancer :
An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55
Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58

Showing the most recent 10 out of 826 publications